Avidity Biosciences, Inc. — Director's Dealing 2020

Jun 12, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2020-06-11

Reporting Person: LEVIN ARTHUR A (Chief Scientific Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	294143	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$0.00		Common Stock (16751)		Indirect
Stock Option (Right to Buy)	$1.24	2030-02-18	Common Stock (211108)		Direct
Stock Option (Right to Buy)	$0.53	2027-08-28	Common Stock (47405)		Direct

Footnotes

F1: The 35,337 shares of Series A Preferred Stock are convertible at any time, at the holder's election, at a ratio of one-for-2.1095 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock will automatically convert at a ratio of one-for-2.1095 shares of the Issuer's common stock. The Series A Preferred Stock has no expiration date.

F2: 25% of the shares subject to the option will vest on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.

F3: This option is exercisable as to vested and unvested shares. The option is currently vested with respect to 17,777 shares, and will vest with respect to the remaining shares in 15 equal monthly installments beginning on June 29, 2020.